Overview

Study That Tests AD109 in Patients Taking GLP-1 Drugs

Status:
COMPLETED

Trial end date:
2024-12-26

Target enrollment:

Participant gender:

Summary

Phase 2 Safety, Efficacy and, Tolerability of Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) in Obstructive Sleep Apnea Patients Taking Tirzepatide, Semaglutide or Liraglutide

Phase:

PHASE2

Details

Lead Sponsor:

Apnimed